Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 45 Univ. Hospitals to Consider Joint Purchases
June 29, 2009
- New Dosage, Treatment Regimens Expected to Become Patentable
June 29, 2009
- GENERICS NEWS IN BRIEF
June 29, 2009
- Revised Pricing Rule Had Little Effect on Pricing of New Drugs in FY2008: FPMAJ
June 29, 2009
- Prof. Kudo Calls For Proper Use of Nexavar for HCC
June 29, 2009
- Range of Drugs Eligible for Price Protection Proposed by FPMAJ Is Reasonable: Report
June 29, 2009
- Sorafenib May Be Used in Wide Range of Patients
June 29, 2009
- Sales of Ethical Drugs Up 0.2% in April
June 29, 2009
- Tamiflu Is Not Ineffective against Resistant Viruses
June 29, 2009
- BUSINESS NEWS IN BRIEF
June 29, 2009
- Pandemic of New-Type Flu Infections Unavoidable in Japan in Oct-Nov: Prof. Oshitani
June 29, 2009
- TOPICS 2 articles
June 29, 2009
- Memantine Dosage Titration Necessary in Patients with Renal Disorders
June 29, 2009
- Zithromac Leaps to Top Place in April: Rep Track Survey
June 29, 2009
- Expert Committee Recommends HbA1C for Diagnosis of Diabetes
June 29, 2009
- Distribution Business Reform in FY2008 Was Failure: Mr Matsutani
June 29, 2009
- Larger-Scale, Dose-Finding PII Studies Necessary for Anticoagulants: Dr C.M. Gibson
June 22, 2009
- Give Incentives to Those Who Settle Prices Earlier: Mr Bessho
June 22, 2009
- New Antithrombotic Drugs That Solve Dilemma of Thrombotic Events and Hemorrhagic Events Needed: Prof. Goto
June 22, 2009
- Mediceo Paltac to Invest in Drug Wholesaler in China
June 22, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…